Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) rose 2% during mid-day trading on Friday . The stock traded as high as $13.89 and last traded at $13.77, with a volume of 136,440 shares traded. The stock had previously closed at $13.50.

BLCM has been the topic of several recent research reports. Zacks Investment Research downgraded Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 17th. SunTrust Banks Inc. initiated coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Bellicum Pharmacueticals has an average rating of “Buy” and a consensus price target of $28.00.

The firm has a 50-day moving average of $12.92 and a 200-day moving average of $11.48. The stock’s market cap is $371.70 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. Equities analysts expect that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.

In other Bellicum Pharmacueticals news, COO Annemarie Moseley sold 25,000 shares of Bellicum Pharmacueticals stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total value of $325,000.00. Following the completion of the sale, the chief operating officer now owns 18,486 shares of the company’s stock, valued at approximately $240,318. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Ken Moseley sold 15,000 shares of Bellicum Pharmacueticals stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the vice president now directly owns 15,196 shares of the company’s stock, valued at approximately $197,548. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley raised its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.